The second renewal of China's Drug-Eluting Stent (DES) VBP shows rising price ceilings and a significant rebound in market share for MNCs like Abbott and Boston Scientific.
Key Takeaways
- 1.DES pricing saw an uptick to Rmb839-949, indicating the NHSA's focus is shifting toward stabilizing supply and industry economics rather than aggressive price cuts.
- 2.Multinational Corporations (MNCs) are regaining market share, rising from ~32% to ~41% volume share in the second renewal.
- 3.Underlying demand for drug-eluting stents remains strong with a 14% CAGR in submitted volume, supported by the expansion of PCI procedures.
Table of Contents
- VBP tracker
- Related research
- Disclosure Appendix
- GS Factor Profile
- M&A Rank
- Quantum
- Disclosures
- Regulatory disclosures
- Ratings, coverage universe and related definitions
- Global product; distributing entities
- General disclosures
Document Preview
Access the Full Report
Get unlimited access to institutional research reports with a 14-day free trial.
Authors
Chris PanZiyi ChenDavid Roman
Securities
MicroPortAbbottBoston ScientificMedtronic
Themes
VBP Policy EvolutionMNC vs. Domestic Competition
Regions
Asia PacificChina